Innovative BioTherapies, Inc. (IBT) is a privately held,
for-profit company founded in 2003 by H. David Humes of the University of Michigan. IBT is a recognized
leader in extracorporeal blood circuit technologies, with extensive experience guiding medical device
innovations from early product development and clinical validation through the complex regulatory
processes of the U.S. Food and Drug Administration.
In addition to advancing its own therapeutic platforms, IBT conducts
research and development for medical device companies, supporting innovation from early concept through
preclinical and translational evaluation. IBT is a Good Laboratory
Practices (GLP) certified laboratory with the capability to conduct large animal studies and operates at
Biosafety Level 2 (BSL-2), enabling rigorous and compliant evaluation of novel therapeutics and
devices.
Leveraging strong academic partnerships with University of Michigan and
clinical insight, IBT develops transformative therapies that improve outcomes across critical
diseases.
